Phase II Protocol for Porfiromycin Solid Tumors

Thymidine Kinase Activity Levels in Serum Can Identify HR+ Metastatic Breast Cancer Patients with a Low Risk of Early Progression (SWOG S0226)

M Bergqvist;A Nordmark;A Williams;C Paoletti;W Barlow;E Cobain;R Mehta;J Gralow;G Hortobagyi;K Albain;L Pusztai;P Sharma;A Godwin;A Thompson;D Hayes;J Rae Biomarkers Jan 29:1-10

PMid: PMID36647745 | PMC number: PMC10681159

Comparing the Prognostic and Predictive Utility of Serum Thymidine Kinase 1 and CA 15-3 in Patients with Hormone Receptor Positive Metastatic Breast Cancer Starting First-Line Endocrine Therapy in SWOG S0226

E Cobain;W Barlow;C Paoletti;M Bergqvist;A Williams;H Ritzen;R Mehta;J Gralow;G Hortobagyi;K Albain;L Pusztai;P Sharma;A Godwin;A Thompson;D Hayes;J Rae J Clin Oncol 41, 2023 (suppl 16; abstr 1076); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session

Effects of CYP3A4 and CYP2C9 genotype on systemic anastrozole and fulvestrant concentrations in SWOG S0226

D Rutherford;S Medley;N Henderson;C Gersch;T Vandenberg;K Albain;S Dakhil;N Tirumali;J Gralow;G Hortobagyi;L Pusztai;R Mehta;D Hayes;K Kidwell;NL Henry;W Barlow;J Rae;D Hertz Pharmacogenomics Aug;24(12):665-673

PMid: PMID37615099 | PMC number: PMC10565537

Evaluating Serum Thymidine Kinase 1 in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Trial

C Paoletti;W Barlow;E Cobain;M Bergqvist;R Mehta;J Gralow;G Hortobagyi;K Albain;L Pusztai;P Sharma;A Godwin;A Thompson;D Hayes;J Rae Clinical Cancer Research, Nov 15;27(22):6115-6123

PMC number: PMID34521624

Healthcare utilization and cost of care in elderly breast cancer patients enrolled in SWOG clinical trials

D Hershman;C Till;J Wright;M Accordino;R Vaidya;W Barlow;S Ramsey;J Unger Breast Cancer Research and Treatment Jun;181(2):455-463

PMid: PMID32306168 | PMC number: PMC8218818

Evaluating Serum Thymidine Kinase 1 (TK1) as a Prognostic and Predictive Marker in Estrogen Receptor (ER) Positive Metastatic Breast Cancer (MBC) Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Trial

C Paoletti;W Barlow;M Bergqvist;R Mehta;J Gralow;G Hortobagyi;K Albain;L Pusztai;P Sharma;A Godwin;A Thompson;D Hayes;J Rae San Antonio Breast Cancer Symposium (December 8-12, 2020, San Antonio TX), poster presentation, abst. PS2-04

Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer

R Mehta;W Barlow;K Albain;T Vandenberg;S Dakhil;N Tirumali;DL Lew;D Hayes;J Gralow;H Linden;R Livingston New England Journal of Medicine Mar 28;380(13):1226-1234

PMid: PMID30917258 | PMC number: PMC6885383

Survival by Hispanic Ethnicity among Cancer Patients Participating in SWOG Clinical Trials

M Chavez-MacGregor;J Unger;A Moseley;S Ramsey;DL Hershman Cancer Apr 15;124(8):1760-1769; Jan 25 [Epub ahead of print]

PMid: PMID29370458 | PMC number: PMC5963502

Association of Cardiovascular Risk Factors With Cardiac Events and Survival Outcomes Among Patients With Breast Cancer Enrolled in SWOG Clinical Trials

D Hershman;C Till;S Shen;J Wright;S Ramsey;W Barlow;J Unger Journal of Clinical Oncology Sep 10;36(26):2710-2717

PMid: PMID29584550 | PMC number: PMC6127026

Value of Anti-Cancer Drugs in SWOG Phase III Clinical Trials: Evidence from Multiple Evaluation Mechanisms

V Nghiem;R Vaidya;M Banegas;D Hershman;J Unger AcademyHealth Annual Research Meeting (June 23-26, 2018, Seattle, WA), poster #B-335

Survival by Hispanic Ethnicity Among Cancer Patients participating in SWOG Clinical Trials

A Moseley;M Chavez-MacGregor;J Unger;S Ramsey;D Hershman Society for Clinical Trials Annual Meeting (May 20-23 2018, Portland, OR), oral presentation

History of diabetes and outcome among participants 65 or older in SWOG clinical trials

DL Hershman;C Till;JD Wright;S Ramsey;W Barlow;J Unger JCO Clinical Cancer Informatics Nov;1:1-12; DOI: https://doi.org/10.1200/CCI.17.00040 Publishedonlineonascopubs.org/journal/ccion November 20, 2017.

PMid: PMID30657402 | PMC number: PMC6640843

The effect of positive SWOG treatment trials on survival of patients with cancer in the US population

JM Unger;M Leblanc;CD Blanke JAMA Oncology Oct 1;3(10):1345-1351

PMid: PMID28586789; PMC5710507

The impact of positive SWOG treatment trials on population survival

J Unger;M LeBlanc;C Blanke J Clin Oncol 35, 2017 (suppl; abstr 6513); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster discussion

A phase III randomized trial of anastrozole and fulvestrant versus anastrozole or sequential anastrozole and fulvestrant as first-line therapy for postmenopausal women with metastatic breast cancer: Final survival outcomes of SWOG S0226

R Mehta;W Barlow;K Albain;T Vandenberg;S Dakhil;N Tirumali;D Lew;D Hayes;J Gralow;H Linden;R Livingston;G Hortobagyi San Antonio Breast Cancer Symposium (December 5-9, 2017, San Antonio, TX), poster discussion

Association Between Cardiovascular Risk Factors and Cardiac Events Among Breast Cancer Patients Enrolled in SWOG Clinical Trials

D Hershman;C Till;J Wright;S Ramsey;W Barlow;JM Unger San Antonio Breast Cancer Symposium (December 5-9, 2017, San Antonio, TX), poster

Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226

D Hertz;W Barlow;K Kidwell;K Albain;T Vandenberg;S Dakhil;N Tirumali;R Livingston;J Gralow;D Hayes;G Hortobagyi;R Mehta;J Rae British Journal of Clinical Pharmacology Jun;81(6):1134-1141; 2016 Feb 9 [Epub ahead of print]

PMid: PMID26859101 | PMC number: PMC4876171

Association between gene variants in SULT1A1 and UGT1A4 and disease outcomes in patients enrolled in SWOG S0226 and treated with anastrozole alone or in combination with fulvestrant for metastatic breast cancer

S Kadlubar;W Barlow;R Mehta;J Daniels;K Albain;T Vandenberg;S Dakhil;N Tirumali;D Lew;J Gralow;R Livingston;G Hortobagyi;D Hayes;JM Rae San Antonio Breast Cancer Symposium (December 8-12, 2015, San Antonio, TX), poster, abst.# P3-07-64;

Combination anastrozole and fulvestrant in metastatic breast cancer: SWOG S0226

R Mehta;W Barlow;K Albain;T Vandenberg;S Dakhil;N Tirumali;DL Lew;DF Hayes;JR Gralow;R Livingston;GN Hortobagyi New England Journal of Medicine 367(5):435-444;

PMid: PMID22853014 | PMC number: PMC3951300

A phase III randomized trial of anastrozole versus anastrozole and fulvestrant as first-line therapy for postmenopausal women with metastatic breast cancer: SWOG S0226

R Mehta;W Barlow;K Albain;T Vandenberg;S Dakhil;N Tirumali;D Lew;D Hayes;J Gralow;R Livingston;G Hortobagyi San Antonio Breast Cancer Symposium 2011 Meeting, abst. S1-1;oral presentation;